Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00137358
Status:
WITHDRAWN
Last Update Posted:
2013-01-24
First Post:
2005-08-26
Brief Title:
Radiation With Chemotherapy and a Study Drug to the Para-Aortic Nodes in Cervical Cancer
Sponsor:
University of Alabama at Birmingham
Organization:
University of Alabama at Birmingham
Study Overview
Official Title:
Phase I Trial of Dose Escalated IMRT to the Para-aortic Nodes With Concurrent Cisplatin and Amifostine in Locally Advanced Cervical Cancer
Status:
WITHDRAWN
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
unable to obtain funding to conduct study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Investigator has since decided not to pursue this protocol further No patients were enrolled
This study is to determine the maximum tolerated dose of external beam radiation to the para-aortic lymph nodes using intensity modulated radiation therapy IMRT
This protocol will test the hypothesis that the use of IMRT and amifostine will decrease GI toxicity and therefore allow the radiation dose to the para-aortic lymph nodes to be safely escalated
This study is to determine the maximum tolerated dose of external beam radiation to the para-aortic lymph nodes using intensity modulated radiation therapy IMRT
This protocol will test the hypothesis that the use of IMRT and amifostine will decrease GI toxicity and therefore allow the radiation dose to the para-aortic lymph nodes to be safely escalated
Detailed Description:
This is a Phase I open-label multi-institutional study that will enroll a minimum of 27 and up to 42 patients with locally advanced cervical cancer a minimum of 27 will be entered if all dose levels are explored without reaching a dose limiting toxicity at any level The primary objective is to determine the maximum tolerated dose MTD of external beam radiation to the para-aortic lymph nodes using IMRT and amifostine Patients will be stratified according to gross tumor volume GTV prior to dose escalation
Within each GTV stratum the dose escalation will be determined as follows Accrue 3 patients in the first dose level based on the determined stratum A Dose Limiting Toxicity is defined as the development of Grade 3 acute GI toxicity per the RTOG acute toxicity scale If no DLT is observed at the first dose level 3 patients will be enrolled at the next dose level If one patient experiences DLT at a given dose level 3 additional patients will be enrolled at that dose level If 0 of these 3 additional patients experience DLT dosing of the next dose level is begun If 1 or more of these 3 additional patients experience DLT at the highest dose level below the maximally administered dose this dose becomes the recommended dose At least 6 patients must be entered at this recommended dose The Maximum Tolerated Dose MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity
Within each GTV stratum the dose escalation will be determined as follows Accrue 3 patients in the first dose level based on the determined stratum A Dose Limiting Toxicity is defined as the development of Grade 3 acute GI toxicity per the RTOG acute toxicity scale If no DLT is observed at the first dose level 3 patients will be enrolled at the next dose level If one patient experiences DLT at a given dose level 3 additional patients will be enrolled at that dose level If 0 of these 3 additional patients experience DLT dosing of the next dose level is begun If 1 or more of these 3 additional patients experience DLT at the highest dose level below the maximally administered dose this dose becomes the recommended dose At least 6 patients must be entered at this recommended dose The Maximum Tolerated Dose MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None